Outrun Therapeutics

Next week, Outrun Therapeutics CEO Carolyn Porter will be attending the 7th Annual TPD & Induced Proximity Summit in Boston, MA organised by Hanson Wade Group.   Held between the 28-31 October, the Summit is the world's definitive meeting in the field of targeted protein degradation and induced proximity.   Carolyn is looking forward to discussing ways to progress the discovery and development of therapeutically relevant protein degraders, blockers, stabilisers, and inducers of protein-protein interactions.   If you are also attending, please reach out to learn more about our proprietary discovery platform to identify first-in-class small molecule drugs targeting E3 ligases.   #drugdiscovery #e3ligases #proteinstabilisation

Despite the high interest in E3 ligases as a therapeutic target, they have been difficult to target in the past.   At Outrun Therapeutics, we combine our world class knowledge of E3 ligase biology and protein interactions with our proprietary discovery platform to identify first-in-class small molecule drugs targeting E3 ligases.   Our X-E3L (Crosslinking E3 Labeller) platform is able to simplify, scale, and modulate the assessment of E3 ligase targets, significantly reducing discovery time and enabling the generation of E3 ligase inhibitors that stabilise proteins.   To learn more about our elegant, engineered platform and how it is enabling us to build a robust pipeline of first-in-class, small molecule E3 ligase inhibitors to prevent protein degradation, visit our website linked in the comments below.   #e3ligase #proteinstabilisation #drugdiscovery

Outrun Therapeutics is the leading E3 ligase inhibitor and protein stabilisation specialist. Our approach can be applied to a wide range of indications, including #oncology and #neurology. Find out how E3 ligases are stabilised to treat disease by watching below or visit our website using the link in the comments.   #drugdiscovery #e3ligase #proteinstabilisation

Outrun Therapeutics will be in Cavtat-Dubrovnik, Croatia from the 27 September to 1 October, attending the 'Ubiquitin and ubiquitin-like proteins in health and disease' EMBO workshop. With the progression of scientific understanding of the ubiquitin proteasome system (UPS) its potential to impact human health is becoming clearer. This workshop will explore the role of ubiquitin and ubiquitin-like modifications (Ubls) in different biological settings. As the E3 ligase inhibitor and protein stabilisation specialist, we are using our X-E3L (Crosslinking E3 Labeller) platform to build a pipeline of small molecule, first-in-class, E3 ligase inhibitors to prevent protein degradation. Our scientist Lee Armstrong is looking forward to attending so please reach out if you would like to find out more about our innovative protein-stabilisation approach. #proteinstabilisation #e3ligase #drugdiscovery

🚀 Outrun Therapeutics Welcomes a New Team Member 🚀 We are thrilled to welcome Sam K. to our team as our new Office Manager and Executive Assistant! 🎉 Sam has over two decades of experience in both client-facing and corporate support roles across numerous sectors and will provide critical support to ensure the smooth running of operations at Outrun. Welcome, Sam! Find out more about Sam and the rest of our amazing team below. https://lnkd.in/ei48KYcT #Welcome #TeamUpdate #OfficeManager #NewHire

🌟 Exciting News from Outrun Therapeutics 🌟 We are excited to announce the opening of a new office at Milton Park (Oxfordshire) in Oxford, UK! Our new Oxford office will serve as a hub for collaboration, giving us a foothold in the heart of the UK’s vibrant scientific community in the Golden Triangle. Stay tuned for more updates and join us in celebrating this exciting new chapter for Outrun Therapeutics. #Biotech #DrugDiscovery #Innovation #Oxford #NewBeginnings

☀ Outrun Therapeutics recently had our summer party in 'sunny' Dundee! ☀ The day began with clay pigeon target sports during which our company value of tenacity was clearly on display. We then ventured out onto the silvery Tay and got to know the local dolphins who put on a show for us. This was followed by good food, a few drinks and great discussions about the future of Outrun Therapeutics. Exciting times ahead! 😎 #SummerParty #TeamBuilding #Tenacity #Collaboration #Integrity

We are delighted to share that Outrun Therapeutics has made the Nature awards #SpinoffPrize Longlist! Pleased to be among 11 #spinouts shortlisted for these awards from across Europe.

The Outrun Therapeutics team including founder Professor Satpal Virdee and Senior scientist Iain Phair participated in Day 3 of the TPD conference marking the opening of the Centre for Targeted Protein Degradation in Dundee. Looking forward to hearing their feedback!

Great to have the opportunity to present Outrun Therapeutics at #BioEquityEurope 2024 in San Sebastian! Excellent panels with insightful comments on key industry topics #biotech #fundraising #dealmaking